Post-earnings recap
Reported
Thu, Jul 23, 2026
EPS actual
$2.37
EPS est.
$2.08
EPS surprise
+14.11%
1-day move
-0.82%
West Pharmaceutical Services reported a better-than-expected EPS for the quarter, which indicates strong profitability. However, the stock reacted negatively, declining by 0.82%. The lack of revenue data and guidance may have contributed to investor uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.37 | N/A | +14.11% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.
West Pharmaceutical Services, Inc. (WST) is a key player in the health care sector, specializing in life sciences tools and services. The company provides essential products and services that support the development and manufacturing of pharmaceuticals and biologics, which are crucial in today's health care landscape.
Last quarter
In Q1-2026, West Pharmaceutical Services reported an EPS of $2.13, which was significantly higher than the expected $1.68, resulting in a 12.86% increase in stock price the following day. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+17.05%
Avg 1-day reaction
+2.31%
Overall, expectations are mixed as the company has a strong track record of beating EPS estimates, but the lack of revenue guidance creates uncertainty. Investors will be keen to see if the company can maintain its momentum.
Bull case
If West Pharmaceutical continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially leading to a significant stock price increase.
Bear case
Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price, especially given the high implied volatility.
The print will turn on these.
Q1
What will be the reported EPS for Q2-2026?
Given West Pharmaceutical's strong history of EPS surprises, this figure will be crucial for investor sentiment and stock performance.
Q2
What are the revenue figures for Q2-2026?
Revenue growth is essential for understanding the company's overall health and market position, especially in the competitive life sciences sector.
—
Est. EPS
$4.19
Est. Rev
$1.2B
Impl. Move
±16.2%
Why consensus could be wrong
The Street may be underestimating West Pharmaceutical's ability to innovate and capture market share, particularly in emerging markets.
Supporting evidence
The company has consistently beaten EPS estimates, indicating strong operational execution.
Recent trends in the life sciences sector suggest increased demand for their products, which may not be fully reflected in current estimates.
Key risk
If the reported EPS significantly exceeds expectations, it could challenge the current cautious outlook.
Pre-commit to what would confirm each case.
The market is debating whether West Pharmaceutical can sustain its growth trajectory in a challenging economic environment.
Bull confirmed if
An EPS of $2.20 or higher would confirm the bull case, indicating strong operational performance.
Bear confirmed if
An EPS below $1.80 would confirm the bear case, suggesting potential issues in profitability.
What the market is pricing for the move.
Implied Move
±17.16%
Historical Avg
±13.2%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±17.2% while WST has averaged ±13.2% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
44.2%
Smart-money positioning from the most recent 13F filings.
Institutional
101.96%
of float
Insider
0.66%
of float
Holders
1,212
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
6,651,784 sh · $2.4B
9.45%
-2.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If West Pharmaceutical beats expectations, history suggests a potential stock increase of around 2.75%, confirming strong operational health.
In line / cautious
If results are in line but cautious, the stock may see muted movement as investors digest management commentary.
Miss
A miss could lead to a decline of around 14.40%, reflecting disappointment and concerns about future growth.
The lines on the call that would change the story.
Vanguard Capital Management LLC
4,613,134 sh · $1.7B
6.56%
-1.5%
Vanguard Portfolio Management LLC
4,015,766 sh · $1.5B
5.71%
-1.9%
FMR, LLC
3,574,816 sh · $1.3B
5.08%
186.0%
State Street Corporation
3,348,698 sh · $1.2B
4.76%
1.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.